Literature DB >> 24955057

Asymptomatic young man with Danon disease.

Jiwon Kim1, Parag Parikh1, Mohammad Mahboob1, James A Arrighi1, Michael K Atalay1, Ethan J Rowin1, Martin S Maron1.   

Abstract

Danon disease is a rare, codominant X-linked genetic disorder characterized by the triad of left ventricular hypertrophy, mental retardation, and peripheral myopathy. This disease is caused by mutations in the gene that encodes lysosomal associated membrane protein 2 (LAMP2), a deficiency of which results in the accumulation of autophagic granular débris within the vacuoles of muscle cells. This is a report of an asymptomatic 19-year-old man with Danon disease in the absence of mental retardation or clinically significant skeletal myopathy. This case underscores the importance of accurate diagnosis of unexplained left ventricular hypertrophy, in order to establish an appropriate treatment plan and to advise genetic counseling.

Entities:  

Keywords:  Cardiomyopathy, hypertrophic/diagnosis; defibrillators, implantable; glycogen storage cardiomyopathy; glycogen storage disease type IIb/diagnosis; hypertrophic cardiomyopathy/diagnosis; left ventricular hypertrophy/etiology; lysosomal storage diseases/genetics/pathology; lysosome-associated membrane glycoproteins; magnetic resonance imaging; male; membrane glycoproteins/deficiency; sarcomeres; young adult

Mesh:

Substances:

Year:  2014        PMID: 24955057      PMCID: PMC4060354          DOI: 10.14503/THIJ-13-3279

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  8 in total

1.  Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease.

Authors:  Andoni Echaniz-Laguna; Michel Mohr; Eric Epailly; Ichizo Nishino; Philippe Charron; Pascale Richard; Christophe Guiraud-Chaumeil; Christine Tranchant
Journal:  Muscle Nerve       Date:  2006-03       Impact factor: 3.217

2.  Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children.

Authors:  Zhao Yang; Colin J McMahon; Liana R Smith; Jeathrina Bersola; Adekunle M Adesina; John P Breinholt; Debra L Kearney; William J Dreyer; Susan W Denfield; Jack F Price; Michelle Grenier; Naomi J Kertesz; Sarah K Clunie; Susan D Fernbach; James F Southern; Stuart Berger; Jeffrey A Towbin; Karla R Bowles; Neil E Bowles
Journal:  Circulation       Date:  2005-09-06       Impact factor: 29.690

3.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy.

Authors:  Michael Arad; Barry J Maron; Joshua M Gorham; Walter H Johnson; J Philip Saul; Antonio R Perez-Atayde; Paolo Spirito; Gregory B Wright; Ronald J Kanter; Christine E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

4.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Paolo Spirito; Win-Kuang Shen; Tammy S Haas; Francesco Formisano; Mark S Link; Andrew E Epstein; Adrian K Almquist; James P Daubert; Thorsten Lawrenz; Giuseppe Boriani; N A Mark Estes; Stefano Favale; Marco Piccininno; Stephen L Winters; Massimo Santini; Sandro Betocchi; Fernando Arribas; Mark V Sherrid; Gianfranco Buja; Christopher Semsarian; Paolo Bruzzi
Journal:  JAMA       Date:  2007-07-25       Impact factor: 56.272

Review 5.  Clinicopathological features of genetically confirmed Danon disease.

Authors:  K Sugie; A Yamamoto; K Murayama; S J Oh; M Takahashi; M Mora; J E Riggs; J Colomer; C Iturriaga; A Meloni; C Lamperti; S Saitoh; E Byrne; S DiMauro; I Nonaka; M Hirano; I Nishino
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

6.  Natural history of Danon disease.

Authors:  Dana Boucek; Jean Jirikowic; Matthew Taylor
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

7.  Cardiovascular magnetic resonance findings in a case of Danon disease.

Authors:  Dorota Piotrowska-Kownacka; Lukasz Kownacki; Marek Kuch; Ewa Walczak; Agnieszka Kosieradzka; Anna Fidzianska; Leszek Krolicki
Journal:  J Cardiovasc Magn Reson       Date:  2009-04-29       Impact factor: 5.364

8.  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy.

Authors:  Barry J Maron; William C Roberts; Michael Arad; Tammy S Haas; Paolo Spirito; Gregory B Wright; Adrian K Almquist; Jeanne M Baffa; J Philip Saul; Carolyn Y Ho; Jonathan Seidman; Christine E Seidman
Journal:  JAMA       Date:  2009-03-25       Impact factor: 56.272

  8 in total
  2 in total

1.  A novel LAMP2 p.G93R mutation associated with mild Danon disease presenting with familial hypertrophic cardiomyopathy.

Authors:  Jing Xu; Lu Wang; Xiangdong Liu; Qiming Dai
Journal:  Mol Genet Genomic Med       Date:  2019-08-28       Impact factor: 2.183

Review 2.  Update Review about Metabolic Myopathies.

Authors:  Josef Finsterer
Journal:  Life (Basel)       Date:  2020-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.